Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jennifer D Bright, Heather N Schultz, Jennifer A Byrne & Robert K Bright. (2013) Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. OncoImmunology 2:7.
Read now
Read now
Jean-Marc Limacher, Clémentine Spring-Giusti, Nadine Bellon, Philippe Ancian, Ronald Rooke & Jean-Yves Bonnefoy. (2013) Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer. Expert Review of Vaccines 12:3, pages 263-270.
Read now
Read now
Shifang Yuan, Changhong Shi, Li Liu & Wei Han. (2010) MUC1-based recombinant Bacillus Calmette–Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opinion on Biological Therapy 10:7, pages 1037-1048.
Read now
Read now
Thomas M Luby. (2008) Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Review of Vaccines 7:7, pages 995-1003.
Read now
Read now
Choon-Kit Tang, Maria Katsara & Vasso Apostolopoulos. (2008) Strategies used for MUC1 immunotherapy: human clinical studies. Expert Review of Vaccines 7:7, pages 963-975.
Read now
Read now
Bruce Acres & Jean-Yves Bonnefoy. (2008) Clinical development of MVA-based therapeutic cancer vaccines. Expert Review of Vaccines 7:7, pages 889-893.
Read now
Read now
Jillian R. Brown, Brett E. Crawford & Jeffrey D. Esko. (2007) Glycan Antagonists and Inhibitors: A Fount for Drug Discovery. Critical Reviews in Biochemistry and Molecular Biology 42:6, pages 481-515.
Read now
Read now
Xiu Feng Hu, Eunice Yang, Jie Li & Pei Xiang Xing. (2006) MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Review of Anticancer Therapy 6:8, pages 1261-1271.
Read now
Read now
Articles from other publishers (58)
Aviyah Peri, Nadja Salomon, Yochai Wolf, Sebastian Kreiter, Mustafa Diken & Yardena Samuels. (2023) The landscape of T cell antigens for cancer immunotherapy. Nature Cancer 4:7, pages 937-954.
Crossref
Crossref
Lixin Yin, Yang Zhou, Sheng Hong, Feiqing Ding & Hui Cai. (2023) Strategies for Synthesizing and Enhancing the Immune Response of Cancer Vaccines Based on MUC1 Glycopeptide Antigens. ChemBioChem 24:10.
Crossref
Crossref
Saru Basnet, Joao M. Santos, Dafne C.A. Quixabeira, James H.A. Clubb, Susanna A.M. Grönberg-Vähä-Koskela, Victor Arias, Santeri Pakola, Tatiana V. Kudling, Camilla Heiniö, Riikka Havunen, Victor Cervera-Carrascon, Suvi Sorsa, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2023) Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors. Molecular Therapy - Oncolytics 28, pages 59-73.
Crossref
Crossref
Atefeh Arab, Amin Reza Nikpoor, Peyman Asadi, Reza Iraei, Rezvan Yazdian-Robati, Afsana Sheikh & Prashant Kesharwani. (2022) Virus-like nanoparticles (VLPs) based technology in the development of breast cancer vaccines. Process Biochemistry 123, pages 44-51.
Crossref
Crossref
Jin-Hong Sui, Yun-Yun Wei, Jin Li & Zhang-Run Xu. (2022) A portable multicolor aptasensor for MUC1 detection based on enzyme-mediated cascade reaction. Microchemical Journal 183, pages 108071.
Crossref
Crossref
Jingwen Hong, Guoxiang Guo, Suxin Wu, Shengzhe Lin, Zhifeng Zhou, Shuping Chen, Chunmei Ye, Jieyu Li, Wansong Lin & Yunbin Ye. (2022) Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer. Journal of Leukocyte Biology 112:6, pages 1577-1590.
Crossref
Crossref
Hanna Huebner, Lothar Häberle, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Visnja Fink, Fabienne Schochter, Inga Bekes, Sven Mahner, Julia Jückstock, Naiba Nabieva, Andreas Schneeweiss, Hans Tesch, Sara Brucker, Jens-Uwe Blohmer, Tanja Fehm, Georg Heinrich, Mahdi Rezai, Matthias Beckmann, Peter Fasching, Wolfgang Janni & Brigitte Rack. (2022) MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers 14:7, pages 1721.
Crossref
Crossref
Jue Hou, Zongsheng He, Tian Liu, Dongfeng Chen, Bin Wang, Qinglian Wen & Xi Zheng. (2022) Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. Frontiers in Oncology 12.
Crossref
Crossref
Noraini Abd-Aziz & Chit Laa Poh. (2022) Development of Peptide-Based Vaccines for Cancer. Journal of Oncology 2022, pages 1-17.
Crossref
Crossref
Ms. Shubhangi Manikpriya, Mr. Akash Shinde, Dr. Gajanan Sanap, Mr. Aniket Bankar & Mr. Shubham Girnare. (2022) Liposomes as a Novel Drug Delivery System. International Journal of Advanced Research in Science, Communication and Technology, pages 30-39.
Crossref
Crossref
Jianwei Zhu, Yun Yuan, Xiaoyu Wan, Dan Yin, Rui Li, Wenwen Chen, Chen Suo & Huan Song. (2021) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database of Systematic Reviews 2021:12.
Crossref
Crossref
Ying Zhao, Zixiang Lin, Zhaoyan Lin, Chaoyu Zhou, Gang Liu, Jiahao Lin, Di Zhang & Degui Lin. (2020) Overexpression of Mucin 1 Suppresses the Therapeutical Efficacy of Disulfiram against Canine Mammary Tumor. Animals 11:1, pages 37.
Crossref
Crossref
Min Jung Kim, Jong Rip Choi, Nara Tae, Tae Min Wi, Kristine M. Kim, Dae Hee Kim & Eung Suk Lee. (2020) Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells. International Journal of Molecular Sciences 21:9, pages 3258.
Crossref
Crossref
Atefeh Razazan & Javad Behravan. (2019) Single peptides and combination modalities for triple negative breast cancer. Journal of Cellular Physiology 235:5, pages 4089-4108.
Crossref
Crossref
Jing-Jing Du, Chang-Wei Wang, Wen-Bo Xu, Lian Zhang, Yuan-Kai Tang, Shi-Hao Zhou, Xiao-Fei Gao, Guang-Fu Yang & Jun Guo. (2020) Multifunctional Protein Conjugates with Built-in Adjuvant (Adjuvant-Protein-Antigen) as Cancer Vaccines Boost Potent Immune Responses. iScience 23:3, pages 100935.
Crossref
Crossref
Mingjing Li, Zhaoyu Wang, Bocheng Yan, Xiaona Yin, Yue Zhao, Fan Yu, Meng Meng, Yonghui Liu & Wei Zhao. (2019) Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy. MedChemComm 10:12, pages 2073-2077.
Crossref
Crossref
Jing‐Jing Du, Shi‐Yao Zou, Xiang‐Zhao Chen, Wen‐Bo Xu, Chang‐Wei Wang, Lian Zhang, Yuan‐Kai Tang, Shi‐Hao Zhou, Jian Wang, Xu‐Guang Yin, Xiao‐Fei Gao, Zheng Liu & Jun Guo. (2019) Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid‐Dependent Immunodominant Response. Chemistry – An Asian Journal 14:12, pages 2116-2121.
Crossref
Crossref
Didier Dréau, Laura Jeffords Moore, Mike Wu, Lopa Das Roy, Lloye Dillion, Travis Porter, Rahul Puri, Noor Momin, K. Dane Wittrup & Pinku Mukherjee. (2019) Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 9.
Crossref
Crossref
Kevin R. Trabbic, Kaitlyn Whalen, Karin Abarca-Heideman, Li Xia, J. Sebastian Temme, Elijah F. Edmondson, Jeffrey C. Gildersleeve & Joseph J. BarchiJr.Jr.. (2019) A Tumor-Selective Monoclonal Antibody from Immunization with a Tumor-Associated Mucin Glycopeptide. Scientific Reports 9:1.
Crossref
Crossref
Jianwei Zhu, Rui Li, Eva Tiselius, Raheleh Roudi, Olivia Teghararian, Chen Suo & Huan Song. (2017) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur & Philippe Slos. (2017) Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
Mohammadreza Movahedin, Teresa M Brooks, Nitin T Supekar, Naveen Gokanapudi, Geert-Jan Boons & Cory L Brooks. (2016) Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology.
Crossref
Crossref
Boqi Hu, Juan Wang, Yingying Guo, Tanxiu Chen, Weihua Ni, Hongyan Yuan, Nannan Zhang, Fei Xie & Guixiang Tai. (2016) Pre-clinical toxicity and immunogenicity evaluation of a MUC1–MBP/BCG anti-tumor vaccine. International Immunopharmacology 33, pages 108-118.
Crossref
Crossref
Fengtao You, Licui Jiang, Bozhen Zhang, Qiang Lu, Qiao Zhou, Xiaoyang Liao, Hong Wu, Kaiqi Du, Youcai Zhu, Huimin Meng, Zhishu Gong, Yunhui Zong, Lei Huang, Man Lu, Jirong Tang, Yafen Li, Xiaochen Zhai, Xiangling Wang, Sisi Ye, Dan Chen, Lei Yuan, Lin Qi & Lin Yang. (2016) Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Science China Life Sciences 59:4, pages 386-397.
Crossref
Crossref
Yun He, Qin Xie, Yanping Wang, Yong Liang, Xiukun Xu, Yong Li, Jinsheng Miao, Zijun Chen & Yunsen Li. (2016) Liquid chromatography mass spectrometry-based O-glycomics to evaluate glycosylation alterations in gastric cancer. PROTEOMICS - Clinical Applications 10:2, pages 206-215.
Crossref
Crossref
An Xiao, Xiu-Jing Zheng, Chengcheng Song, Yue Gui, Chang-Xin Huo & Xin-Shan Ye. (2016) Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines. Organic & Biomolecular Chemistry 14:30, pages 7226-7237.
Crossref
Crossref
Yonghui Liu, Wenpeng Zhang, Qianqian He, Fan Yu, Tianbang Song, Tingting Liu, Zhenqing Zhang, Jun Zhou, Peng George Wang & Wei Zhao. (2016) Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines. Chemical Communications 52:72, pages 10886-10889.
Crossref
Crossref
P. Mitchell, N. Thatcher, M.A. Socinski, E. Wasilewska-Tesluk, K. Horwood, A. Szczesna, C. Martín, Y. Ragulin, M. Zukin, C. Helwig, M. Falk, C. Butts & F.A. Shepherd. (2015) Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Annals of Oncology 26:6, pages 1134-1142.
Crossref
Crossref
Sebastian Hartmann, Lutz Nuhn, Björn Palitzsch, Markus Glaffig, Natascha Stergiou, Bastian Gerlitzki, Edgar Schmitt, Horst Kunz & Rudolf Zentel. (2015) CpG-Loaded Multifunctional Cationic Nanohydrogel Particles as Self-Adjuvanting Glycopeptide Antitumor Vaccines. Advanced Healthcare Materials 4:4, pages 522-527.
Crossref
Crossref
Bruce Acres, Gisele Lacoste & Jean-Marc Limacher. 2017. Cancer Vaccines. Cancer Vaccines
79
97
.
Reto A. Schwendener. (2014) Liposomes as vaccine delivery systems: a review of the recent advances. Therapeutic Advances in Vaccines 2:6, pages 159-182.
Crossref
Crossref
Huan Song, Jianwei Zhu, Chen Suo & DongHao Lu. (2014) Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Kolsoum Rezaie Kahkhaie, Omeed Moaven, Mohammad Reza Abbaszadegan, Mehdi Montazer & Mehran Gholamin. (2014) Specific MUC1 Splice Variants Are Correlated With Tumor Progression in Esophageal Cancer. World Journal of Surgery 38:8, pages 2052-2057.
Crossref
Crossref
Charles Butts, Mark A Socinski, Paul L Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor-Eliade Ciuleanu, Lionel Bosquée, José Manuel Trigo, Alexander Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Ernst Erich Eberhardt, Christoph Helwig, Andreas Schröder & Frances A Shepherd. (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. The Lancet Oncology 15:1, pages 59-68.
Crossref
Crossref
Brian M. Olson, Laura E. Johnson & Douglas G. McNeel. (2012) The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunology, Immunotherapy 62:3, pages 585-596.
Crossref
Crossref
Hui Cai, Zhan‐Yi Sun, Zhi‐Hua Huang, Lei Shi, Yu‐Fen Zhao, Horst Kunz & Yan‐Mei Li. (2012) Fully Synthetic Self‐Adjuvanting Thioether‐Conjugated GlycopeptideLipopeptide Antitumor Vaccines for the Induction of Complement‐Dependent Cytotoxicity against Tumor Cells. Chemistry – A European Journal 19:6, pages 1962-1970.
Crossref
Crossref
Zhuo‐Ri Li, Jia‐Li Wei, Zhen‐Zhen Li & Shu‐Fang Li. (2013) Mucins 1‐shRNA inhibit the proliferation and HIF‐1alpha protein expression on human cholangiocarcinoma cells. Cell Biology International 37:2, pages 121-125.
Crossref
Crossref
Dima Al Sheikha, Brendan L. Wilkinson, Gajan Santhakumar, Morten Thaysen-Andersen & Richard J. Payne. (2013) Synthesis of homogeneous MUC1 oligomers via a bi-directional ligation strategy. Organic & Biomolecular Chemistry 11:36, pages 6090.
Crossref
Crossref
Satyanarayana Rachagani, María P Torres, Sushil Kumar, Dhanya Haridas, Michael Baine, Muzafar A Macha, Sukhwinder Kaur, Moorthy P Ponnusamy, Parama Dey, Parthasarathy Seshacharyulu, Sonny L Johansson, Maneesh Jain, Kay-Uwe Wagner & Surinder K Batra. (2012) Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
Francesco Giovinazzo, Giulia Turri, Sara Zanini, Giovanni Butturini, Aldo Scarpa & Claudio Bassi. (2012) Clinical implications of biological markers in pancreatic ductal adenocarcinoma. Surgical Oncology 21:4, pages e171-e182.
Crossref
Crossref
Neelima R. Mehta, Gregory T. Wurz, Rebekah A. Burich, Brittany E. Greenberg, Stephen Griffey, Audrey Gutierrez, Katie E. Bell, Jamie L. McCall, Michael Wolf & Michael DeGregorio. (2012) L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice. Clinical Cancer Research 18:10, pages 2861-2871.
Crossref
Crossref
Yi-Long Wu, Keunchil Park, Ross A Soo, Yan Sun, Karin Tyroller, David Wages, Guy Ely, James Chih-Hsin Yang & Tony Mok. (2011) INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 11:1.
Crossref
Crossref
Dahlia M. Besmer, Jennifer M. Curry, Lopamudra D. Roy, Teresa L. Tinder, Mahnaz Sahraei, Jorge Schettini, Sun-Il Hwang, Yong Y. Lee, Sandra J. Gendler & Pinku Mukherjee. (2011) Pancreatic Ductal Adenocarcinoma Mice Lacking Mucin 1 Have a Profound Defect in Tumor Growth and Metastasis. Cancer Research 71:13, pages 4432-4442.
Crossref
Crossref
Brian M. Olson & Douglas G. McNeel. (2011) CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunology, Immunotherapy 60:6, pages 781-792.
Crossref
Crossref
Francisco Corzana, Jesús H. Busto, Filipa MarceloMarisa García de Luis, Juan Luis AsensioSonsoles Martín‐SantamaríaJesús Jiménez‐BarberoAlberto Avenoza & Jesús M. Peregrina. (2011)
Engineering
O
‐Glycosylation Points in Non‐extended Peptides: Implications for the Molecular Recognition of Short Tumor‐Associated Glycopeptides
. Chemistry – A European Journal 17:11, pages 3105-3110.
Crossref
Crossref
Wen-Chuan Wu, Da-Yong Jin, Wen-Hui Lou, Dan-Song Wang & Xin-Yu Qin. (2010) Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer. Journal of Cancer Research and Clinical Oncology 136:12, pages 1861-1868.
Crossref
Crossref
Sharmila Pejawar-Gaddy, Yogendra Rajawat, Zoe Hilioti, Jia Xue, Daniel F. Gaddy, Olivera J. Finn, Raphael P. Viscidi & Ioannis Bossis. (2010) Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology, Immunotherapy 59:11, pages 1685-1696.
Crossref
Crossref
Daniel E. Speiser & Pedro Romero. (2010) Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Seminars in Immunology 22:3, pages 144-154.
Crossref
Crossref
Suzanne K. CoberlyFrancine Z. ChenMark P. ArmaniniYan ChenPeter F. YoungJennie P. MatherDeryk T. Loo. (2009) The RAV12 Monoclonal Antibody Recognizes the N-Linked Glycotope RAAG12: Expression in Human Normal and Tumor Tissues. Archives of Pathology & Laboratory Medicine 133:9, pages 1403-1412.
Crossref
Crossref
Xiaochuan Chen, Wentao Gao, Andrea Gambotto & Olivera J. Finn. (2008) Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy. Cancer Immunology, Immunotherapy 58:6, pages 977-987.
Crossref
Crossref
Francisco Corzana, Jesús H. Busto, Marisa García de Luis, Jesús Jiménez‐Barbero, Alberto Avenoza & Jesús M. Peregrina. (2009) The Nature and Sequence of the Amino Acid Aglycone Strongly Modulates the Conformation and Dynamics Effects of Tn Antigen's Clusters. Chemistry – A European Journal 15:15, pages 3863-3874.
Crossref
Crossref
Seyed Hamid Aghaee BakhtiariFatemeh RahbarizadehSadegh HasanniaDavoud AhmadvandFarnoush Jafari Iri-SoflaMohammad Javad Rasaee. (2009) Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function. Hybridoma 28:2, pages 85-92.
Crossref
Crossref
Pinku Mukherjee, Gargi D. Basu, Teresa L. Tinder, Durai B. Subramani, Judy M. Bradley, Million Arefayene, Todd Skaar & Giovanni De Petris. (2009) Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition. The Journal of Immunology 182:1, pages 216-224.
Crossref
Crossref
Rodryg Ramlau, Elisabeth Quoix, Janusz Rolski, Miklos Pless, Herve Lena, Eric Lévy, Maciej Krzakowski, Dagmar Hess, Eric Tartour, Marie-Pierre Chenard, Jean-Marc Limacher, Nadine Bizouarne, Bruce Acres, Céline Halluard & Thierry Velu. (2008) A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:7, pages 735-744.
Crossref
Crossref
Katja Engelmann, Hongmei Shen & Olivera J. Finn. (2008) MCF7 Side Population Cells with Characteristics of Cancer Stem/Progenitor Cells Express the Tumor Antigen MUC1. Cancer Research 68:7, pages 2419-2426.
Crossref
Crossref
Shuzi Zhang, Haihong Zhang, Heliang Shi, Xianghui Yu, Wei Kong & Wei Li. (2008) Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Human Immunology 69:4-5, pages 250-258.
Crossref
Crossref
Brian M. Olson & Douglas G. McNeel. (2007) Antibody and T‐cell responses specific for the androgen receptor in patients with prostate cancer. The Prostate 67:16, pages 1729-1739.
Crossref
Crossref
Geneviève Monges. (2006) MUC1 et ses applications en pathologie. Annales de Pathologie 26:4, pages 245-246.
Crossref
Crossref